Rationale for the development of noradrenaline reuptake inhibitors

Human Psychopharmacology

Volumn 13, Issue SUPPL. 1, 1998, Pages

  Brunello, Nicoletta ^a,b   Racagni, Giorgio ^b,c  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

Intracellular pathways; Neuroreceptors; Reboxetine; Selective noradrenaline reuptake inhibitor

Indexed keywords

ANTIDEPRESSANT AGENT; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN UPTAKE INHIBITOR;

CONFERENCE PAPER; DEPRESSION; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; NORADRENALIN BRAIN LEVEL; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL;

EID: 0031932254     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199802)13:1+3.0.CO;2-6     Document Type: Conference Paper

References (55)

1. Anderson, I. M. and Tomenson, B. M. (1994). The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. Journal of Psychopharmacology, 8, 238-249.
2. Asberg, M., Träskman, L., Thorén, P. (1976). 5-HIAA in the cerebrospinal fluid: a biochemical suicide prediction. Archives of General Psychiatry, 33, 1193-1197.
3. Asberg, M., Bertilsson, L., Martensson, B., Scalia-Tomba, G.-P., Thorén, P., Träskman-Bendz, L. (1984). CSF monoamine metabolites in melancholia. Acta Psychiatria Scandinavica, 69, 201-219.
4. Ban, T. A., Gaszner, P., Aguglia, E., Batista, R., Castillo, A., Lipcsey, A., Macher, J.-P., Torres-Ruiz, A., Vergara, L. (1998). Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations. Human Psychopharmacology, 13, S29-S39.
5. Banerjee, S. P., Kung, L. S., Riggi, S. S. and Chanda, S. K. (1977). Development of beta adrenergic receptor subsensitivity by antidepressants. Nature, 268, 455-456.
6. Beaumont, G. (1989). The toxicity of antidepressants. British Journal of Psychiatry, 154, 454-458.
7. Berzewski, H., Van Moffaert, M. and Gagiano, C. A. (1997). Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. European Neuropsychopharmacology, 7 (Suppl. 1), S37-S47.
8. Bolden-Watson, C. and Richelson, E. (1993). Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sciences, 52, 1023-1029.
9. Bunney, W., Davis, J. and Davis, J. M. (1965). Norepinephrine in depressive reaction. Archives of General Psychiatry, 13, 483-494.
10. Cookson, J. (1993). Side effects of antidepressants. British Journal of Psychiatry, 163, 20-24.
11. Coppen, A. (1967). The biochemistry of affective disorders. British Journal of Psychiatry, 113, 1237-1264.
12. DeVane, C. L. (1994). Pharmacokinetics of the newer antidepressants: clinical relevance. American Journal of Medicine, 97 (Suppl. 6A), 13S-23S.
13. Duman, R. S., Heninger, G. R. and Nestler, E. J. (1994). Molecular psychiatry. Adaptations of receptor coupled signal transduction pathways underlying stress- and drug-induced neural plasticity. Journal of Nervous and Mental Disease, 182, 692-700.
14. Extein, J., Tallman, J., Smith, C. C. and Goodwin, F. K. (1979). Changes in lymphocyte beta-adrenergic receptors in depression and mania. Psychiatry Research, 1, 191-197.
15. Feighner, J. P. and Boyer, W. F. (1993). Selective serotonin reuptake inhibitors: the clinical use of citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline. In Perspectives in Psychiatry. Volume 1, Wiley, Chichester.
16. Ferrier, I. N., Silverstone, T. and Eccleston, D. (1992). Selective serotonin re-uptake inhibitors in depression. Psychiatric Bulletin, 16, 737-739.
17. Garcia-Sevilla, J. A., Pardo, D., Giralt, M. T., Guimon, J. and Areso, P. (1990). Alpha-2 adrenoreceptor-mediated inhibition of platelet adenylate cyclase and induction of aggregation in major depression: effect of long-term antidepressant drug-treatment. Archives of General Psychiatry, 47, 125-132.
18. Goodwin, F. K. and Post, R. M. (1975). Studies of amine metabolites in affective illness and schizophrenia: a comparative analysis. In Biology of the Major Psychoses, Freidman D. X. et al. (eds), Volume 54, Raven Press, New York, pp. 299-332.
19. Hall, H. and Ogren, S.-O. (1981). Effects of antidepressant drugs on different receptors in the brain. European Journal of Pharmacology, 70, 393-407.
20. Healy, D., Carney, P. A. and Leonard, B. E. (1983). Monoamine related markers of depression. Journal of Psychiatric Research, 7, 251-258.
21. Hyman, S. E. and Nestler, E. J. (1996). Initiation and adaptation: a paradigm for understanding psychotropic drug action. American Journal of Psychiatry, 153, 151-162.
22. Kanof, P. D. and Greengard, P. (1978). Brain histamine receptors as targets for antidepressant drugs. Nature, 272, 329-333.
23. Leonard, B. E. (1986). Neurotransmitter receptors, endocrine responses and the biological substrates of depression: a review. Human Psychopharmacology, 1, 3-18.
24. Leonard, B. E. (1995). SSRI differentiation: pharmacology and pharmcokinetics. Human Psychopharmacology, 10, S149-S151.
25. Leonard, B. E. (1996). New approaches to the treatment of depression. Journal of Clinical Psychiatry, 57 (Suppl. 4), 226-233
26. Maas, J. W., Fawcett, J. and Dekirmenjian, H. (1968). 3-Methoxy-4-Hydroxy Phenylglycol (MHPG) excretion in depressive states. Archives of General Psychiatry, 19, 129-134.
27. Manji, H. K., Chen, G., Shimon, H., Hsiao, J. K., Potter, W. Z. and Belmaker, R. H. (1995). Guanine nucleotide-binding proteins in bipolar affective disorder. Effect of long-term lithium treatment. Archives of General Psychiatry, 52, 135-144.
28. Melloni, P., Carniel, G., Della Torre, A., Bonsignori, A., Buonamici, M., Pozzi, O., Ricciardi, S. and Rossi, A. (1984). Potential antidepressant agents. Alpha-aryloxy-benzyl derivatives of ethanolamine and morpholine. European Journal of Medicinal Chemistry, 19, 235-242.
29. Mitchell, P. B., Beam, J. A., Corn, T. H. and Checkley, S. A. (1988). Growth hormone response to clonidine after recovery in patients with endogenous depression. British Journal of Psychiatry, 142, 34-38.
30. Montgomery, S. A. (1997a). Is there a role for a pure noradrenergic drug in the treatment of depression? European Neuropsychopharmacology, 1 (Suppl. 1) S3-S9.
31. Montgomery, S. A. (1997b). Reboxetine: additional benefits to the depressed patient. Journal of Psychopharmacology, 11(4) (Suppl.) S9-S15.
32. Montgomery, S. A. and Kasper, S. (1995). Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. International Clinical Psychopharmacology, 9 (Suppl. 4) 33-40.
33. Nibuya, M., Morinobu, S. and Duman, R. S. (1995). Regulation of BDNF and trkB mRNA by chronic electroconvulsive seizure and antidepressant drug treatment. Journal of Neuroscience, 15, 7539-7547.
34. Paul, I. A., Nowak, G., Layer, R. T., Popick, P. and Sholnick, P. (1994). Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. Journal of Pharmacology and Experimental Therapeutics, 269, 95-102.
35. Perez, J., Tinelli, D., Brunello, N. and Racagni, G. (1989). cAMP-dependent phopsphorylation of soluble and crude microtubule fractions of rat cerebral cortex after prolonged desmethylimipramine treatment. European Journal of Pharmacology - Molecular Pharmacology Section, 172, 305-316.
36. Perez, J., Tinelli, D., Bianchi, E., Brunello, N. and Racagni, G. (1991). cAMP binding proteins in the rat cerebral cortex after administration of selective 5-HT and NA reuptake blockers with antidepressant activity. Neuropsychopharmacology, 4, 57-64.
37. Perez, J., Zanardi, R., Mori, S., Gasperini, M., Smeraldi, E. and Racagni, G. (1995). Abnormalities of cAMP-dependent endogenous phosphorylation in platelets from patients with Bipolar Disorder. American Journal of Psychiatry, 152, 1204-1206.
38. Peroutka, S. J. and Snyder, S. H. (1980). Long term antidepressant treatment decreases spiroperidol labelled serotonin receptor binding. Science, 210, 88-90.
39. Popoli, M., Perez, J., Vocaturo, C., Garbini, S. and Racagni, G. (1994). Long-term treatment with antidepressant agents affects Ca2 + /calmodulin protein-kinase II in hippocampal presynapses. Neuropsychopharmacology, 10 (Suppl. 3), 13.
40. Popoli, M., Vocaturo, C., Perez, J., Smeraldi, E. and Racagni, G. (1995). Presynaptic Ca2 + /calmodulin-dependent protein kinase II: Autophosphorylation and activity increase in the hippocampus after long-term blockade of serotonin reuptake. Molecular Pharmacology, 48, 623-629.
41. Post, R. M., Gordon, E. K., Goodwin, F. K. and Bunney, W. E. Jr (1973). Central norepinephrine metabolism in affective illness: MHPG in the cerebrospinal fluid. Science, 179, 1002-1003.
42. Potter, W. Z., Rudorfer, M. V. and Manji, H. (1991). The pharmacologie treatment of depression. New England Journal of Medicine, 325, 633-642.
43. Racagni, G., Brunello, N., Tinelli, D. and Perez, J. (1992). New biochemical hypotheses on the mechanism of action of antidepressant drugs: cAMP-dependent phosphorylation system. Pharmacopsychiatry, 25, 51-55.
44. Richelson, E. and Nelson, A. (1984). Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. Journal of Pharmaceutical and Experimental Therapeutics, 230, 94-102.
45. Riva, M., Brunello, N., Rovescalli, A. C., Galimberdi, R., Carfagna, N., Carminati, P., Pozzi, O., Ricciardi, S., Roncucci, R., Rossi, A. and Racagni, G. (1989). Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies. Journal of Drug Development, 1, 243-253.
46. Schatzberg, A. F. and Schildkraut, J. J. (1995). Recent studies on norepinephrine systems in mood disorders. In Psychopharmacology: the Fourth Generation of Progress. Bloom, F. E. and Kupfer, D. J. (eds) Raven Press, New York, pp. 911-920.
47. Schreiber, G., Avissar, S., Danon, A. and Belmaker, R. H. (1991). Hyperfunctional G proteins in mononuclear leukocytes of patients with mania. Biological Psychiatry, 29, 273-280.
48. Serra, G., Collu, M., D'Aquila P. S. and Gessa, G. L. (1992). Role of the mesolimbic dopamine system in the mechanism of action of antidepressants. Pharmacology and Toxicology, 71, 72-85.
49. Shaw, D. M., O'Keeffe, R., MacSweeney, D. A., Brooksbank, B. W. L., Noguera, R. and Coppen, A. (1973). 3-Methoxy-4-hydroxyphenylglycol in depression. Psychological Medicine, 3, 333-336.
50. Shopsin, B., Wilk, S., Gersbon, S., Davis, K. and Sohl, M. (1973). Cerebrospinal fluid MHPG. An assessment of norepinephrine metabolism in affective disorders. Archives of General Psychiatry, 28, 230-233.
51. Siever, L. J., Kafka, M. S., Targum, S. M. and Lake, C. R. (1984). Platelet alpha-adrenergic binding and biochemical responsiveness in depressed patients and controls. Psychiatry Research, 11, 287-302
52. Stokes, P. E. (1993). Fluoxetine: a five year review. Clinical Therapeutics, 15 (2), 216-243.
53. Thomas, D. R., Nelson, D. R. and Johnson, A. M. (1987). Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology, 93, 193-200.
54. Wong, E. H. F., Graveel, C. R. and Smith, M. W. (1997). Pharmacological selectivity of reboxetine: a selective noradrenaline reuptake inhibitor (NARI). Presented at the Annual Meeting of the American College of Neuropsychopharmacology, Hawaii, December, 1997.
55. Zanardi, R., Racagni, G., Smeraldi, E. and Perez, J. (1997). Differential effect of lithium on platelet protein phosphorylation in bipolar patients and healthy subjects. Psychopharmacology, 129, 44-47.